Technical Analysis for LGND - Ligand Pharmaceuticals Incorporated

Grade Last Price % Change Price Change
grade F 106.04 -0.75% -0.80
LGND closed down 0.75 percent on Friday, December 13, 2019, on 63 percent of normal volume. It ran into resistance at its 50 day moving average.

Trend Table & Recent Signals

ADX Long Term Intermediate Term Short Term
Weak or Absent Down Down Down
See historical LGND trend table...

Date Alert Name Type % Chg
20 DMA Resistance Bearish 0.00%
50 DMA Resistance Bearish 0.00%
Non-ADX 1,2,3,4 Bearish Bearish Swing Setup 0.00%
Inside Day Range Contraction -0.75%
50 DMA Resistance Bearish 1.75%
MACD Bearish Centerline Cross Bearish 1.75%
Outside Day Range Expansion 1.75%
50 DMA Resistance Bearish -0.46%
20 DMA Resistance Bearish 0.24%
Fell Below 50 DMA Bearish 0.24%
Older signals for LGND ...

Free Daily (Stock) Chart Reading

Let us help you stay on top of your investments. We will alert you to important technical developments on your portfolio & watchlist.
Configure default chart indicators
Basic chart:

Profile

Ligand Pharmaceuticals Incorporated, a biotechnology company, engages in the acquisition and development of royalty revenue generating assets in the United States. The company's assets include PROMACTA, an oral thrombopoietin receptor agonist therapy for the treatment of adult patients with chronic immune thrombocytopenic purpura; Kyprolis for the treatment of multiple myeloma; AVINZA, a pain therapeutic; Viviant/Conbriza for the treatment of postmenopausal osteoporosis; Nexterone, an injectable formulation; and Viviant (bazedoxifene) for the treatment of postmenopausal osteoporosis. Its late-stage development programs comprise PROMACTA, which is in is in Phase II clinical studies for the treatment of oncology-related thrombocytopenia in patients with solid tumors, sarcoma, and Myelodysplastic Syndrome. The company's late-stage development programs also include Merck Captisol program that is in Phase III studies; Captisol-enabled Clopidogrel, which is in Phase III studies; RE-021 program, a dual acting receptor antagonist that is in various stages of development for indications of severe kidney diseases; Dinaciclib that is in Phase IIb/III adaptive clinical trials for the treatment of patients with refractory chronic lymphocytic leukemia; and Beta-Secretase Inhibitor, which is in Phase II/III studies for treating Alzheimer's disease. In addition, its late-stage development programs comprise Captisol-enabled Delafloxacin, a Phase III clinical trial product for the management of acute seizure disorder; and Captisol-enabled Delafloxacin that is in Phase III clinical trials for the treatment of acute bacterial skin and skin structure infections. The company has alliances with GlaxoSmithKline, Onyx Pharmaceuticals, Merck, Pfizer, Baxter International, Bristol-Myers Squibb, Celgene, Lundbeck Inc., Eli Lilly and Co., Spectrum Pharmaceuticals, and The Medicines Company. Ligand Pharmaceuticals Incorporated was founded in 1987 and is headquartered in La Jolla, California.
Biotechnology Pain Chemical Compounds Organic Compounds Solid Tumors Alzheimer's Disease Multiple Myeloma Myelodysplastic Syndrome Chloroarenes Clinical Trial Product Phenols Skin And Skin Structure Infections Sarcoma Carboxylic Acids Selective Estrogen Receptor Modulators

Is LGND a Buy, Sell or Hold?

Indicator Bull Case Neutral / Hold Bear Case
50 DMA
200 DMA
ADX Trend
Oversold / Overbought
Relative Strength

Indicators

Indicator Value
52 Week High 144.95
52 Week Low 85.0
Average Volume 299,039
200-Day Moving Average 109.71
50-Day Moving Average 107.73
20-Day Moving Average 108.11
10-Day Moving Average 107.23
Average True Range 3.79
ADX 19.51
+DI 13.74
-DI 21.74
Chandelier Exit (Long, 3 ATRs ) 103.12
Chandelier Exit (Short, 3 ATRs ) 113.87
Upper Bollinger Band 114.34
Lower Bollinger Band 101.88
Percent B (%b) 0.33
BandWidth 11.52
MACD Line -0.40
MACD Signal Line 0.16
MACD Histogram -0.5599
Fundamentals Value
Market Cap 2.23 Billion
Num Shares 21.1 Million
EPS 0.41
Price-to-Earnings (P/E) Ratio 258.63
Price-to-Sales 25.74
Price-to-Book 7.36
PEG Ratio 1.53
Dividend 0.00
Dividend Yield 0.00%
Pivot Point Level Traditional / Classic Fibonacci Demark Woodie Camarilla
Resistance 4 (R4) 111.17
Resistance 3 (R3) 111.44 109.99 110.32
Resistance 2 (R2) 109.99 108.69 109.86 110.03
Resistance 1 (R1) 108.02 107.88 107.30 107.75 109.74
Pivot Point 106.57 106.57 106.21 106.44 106.57
Support 1 (S1) 104.60 105.27 103.88 104.33 102.34
Support 2 (S2) 103.15 104.46 103.02 102.05
Support 3 (S3) 101.18 103.15 101.77
Support 4 (S4) 100.91